COX-2 inhibitors: increased risk of CV events?

Author：

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1303, 2001-01, pp. : 21-21

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Do Some Inhibitors of COX-2 Increase the Risk of Thromboembolic Events?: Linking Pharmacology with Pharmacoepidemiology

By Clark D.W.J. Layton D. Shakir S.A.W.

Drug Safety, Vol. 27, Iss. 7, 2004-01 ,pp. : 427-456

Adis International

Access to resources Recommend Favorite

Inhaled anticholinergics: increased risk of major adverse CV events?

Inpharma, Vol. 1, Iss. 1658, 2008-01 ,pp. : 17-17

Adis International

Access to resources Recommend Favorite

NSAIDs and the risk of CV events: is there a class effect?

Inpharma, Vol. 1, Iss. 1492, 2005-01 ,pp. : 21-21

Adis International

Access to resources Recommend Favorite

Do Inhaled Anticholinergics Increase or Decrease the Risk of Major Cardiovascular Events?: A Synthesis of the Available Evidence

By Salpeter Shelley R.

Drugs, Vol. 69, Iss. 15, 2009-10 ,pp. : 2025-2033

Adis International

Access to resources Recommend Favorite

Selective COX-2 inhibitors for acute gout?

Inpharma, Vol. 1, Iss. 1363, 2002-01 ,pp. : 2-2

Adis International

Access to resources Recommend Favorite